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Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies. The
effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially due to methodological
limitations of observational studies. In this study, we investigated the associations of genetic variants in alcohol-metabolising
genes with prostate cancer incidence and survival. We analysed data from 23,868 men with prostate cancer and 23,051 con-
trols from 25 studies within the international PRACTICAL Consortium. Study-specific associations of 68 single nucleotide poly-
morphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs))
with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regres-
sion models, respectively. The data across the 25 studies were meta-analysed using fixed-effect and random-effects models.
We found little evidence that variants in alcohol metabolising genes were associated with prostate cancer diagnosis. Four var-
iants in two genes exceeded the multiple testing threshold for associations with prostate cancer mortality in fixed-effect
meta-analyses. SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio,
HRfixed50.78; 95% confidence interval (95%CI):0.66,0.91; p values50.002); rs12910509, HRfixed50.76; 95%CI:0.64,0.91; p
values50.003); and rs8041922 (HRfixed50.76; 95%CI:0.64,0.91; p values50.002). These SNPs were in linkage disequilibri-
um with each other. In ALDH1B1, rs10973794 (HRfixed51.43; 95%CI:1.14,1.79; p values50.002) was associated with pros-
tate cancer mortality in men with low-grade prostate cancer. These results suggest that alcohol consumption is unlikely to
affect prostate cancer incidence, but it may influence disease progression.
Introduction
Prostate cancer is the most common cancer in men in devel-
oped countries, with 758,700 new cases diagnosed and
142,000 deaths in 2012.1 With increasing uptake of prostate-
speciﬁc antigen (PSA) testing and the ageing population,
prostate cancer incidence is increasing.2 The factors inﬂuenc-
ing prostate cancer incidence and survival after diagnosis are
poorly understood, therefore more evidence is needed.3
Alcohol is a carcinogen associated with oropharyngeal, liv-
er, breast, colorectal and oesophageal cancers.4 Functional
variation in the genes involved in alcohol metabolism result
in altered exposure to the carcinogenic metabolites of etha-
nol, suggesting a mechanism for genetic sensitivity to alcohol
to inﬂuence the pathogenesis of cancers.5 For example, popu-
lations with an increased prevalence of common genetic vari-
ation in the alcohol dehydrogenase gene, that results in
What’s new?
Alcohol may spur prostate cancer progression, though it does not appear to affect incidence, according to new analysis. Varia-
tion in genes involved in alcohol metabolism affect how much the body is exposed to carcinogenic metabolites. These authors
examined 68 genetic variants in alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) genes, seeking a link with
prostate cancer risk. While they found no evidence that these variants alter prostate cancer incidence, they did show that
SNPs in the ALDH1A2 gene affect prostate cancer mortality. From a public health standpoint, these results suggest reducing
alcohol consumption could slow prostate cancer disease progression.
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reduced enzyme activity, have an increased risk of oesopha-
geal cancer compared with populations with the fully active
enzyme.4
At present the role of alcohol use on prostate cancer
remains uncertain. The World Cancer Research Fund’s exten-
sive report based on systematic reviews described the evidence
as limited and inconclusive,6 and the International Association
for Research on Cancer did not list this cancer site amongst
others more apparently caused by alcohol in their Monograph
on alcohol’s carcinogenicity.4 There have been conﬂicting
reports of possible associations of alcohol with various stages
or histological grades of prostate cancer,7–12 and meta-analyses
have highlighted the inconsistencies, emphasising the need for
further research in this area.13,14
The majority of evidence about the effects of alcohol on
prostate cancer is from observational studies. One potential
limitation of traditional observational research is that the
ﬁndings can potentially be explained by common causes of
both exposure and outcome (confounding factors). Other
potential sources of bias are reverse causation and recall bias,
where having prostate cancer affects drinking behaviour or
its reporting, rather than alcohol consumption increasing the
risk of prostate cancer. A prospective study design could mit-
igate both of these problems, but could still be affected by
bias in the form of the “sick quitter” effect, where former
heavy drinkers reduce their alcohol intake in middle-age
because of comorbidities that may be alcohol-related.
Mendelian randomisation is an approach that uses genetic
variants robustly associated with exposures of interest, or
their metabolic effects, as instrumental variables to test the
un-confounded and unbiased causal effects of those expo-
sures and their metabolic effects with cancer.15 Mendelian
randomisation analyses rely on two approximate laws of
Mendelian genetics,15,16 that at meiosis alleles segregate with-
out any inﬂuence of environmental factors and that the
inheritance of one trait is independent of the inheritance of
others. This allows genetic variation to be used in epidemio-
logical studies as an un-confounded proxy for an environ-
mental exposure,15–17 in this case alcohol consumption, to
estimate the inﬂuence of cumulative life-time risk of expo-
sure, to reduce recall bias and the “sick-quitter” effect and to
negate reverse causation. All these features are limitations of
previous conventional observational studies.7,8,13 Mendelian
randomisation has already been used successfully in both car-
diovascular18,19 and cancer epidemiology20–24 to clarify the
causal effects of alcohol on disease.
In this study, we undertook Mendelian randomisation
analyses in which we used variants in alcohol metabolising
genes inﬂuencing metabolism and intake, to test the causal
effect of alcohol exposure on prostate cancer risk and pro-
gression. The motivation is that if alcohol intake causally
increases prostate cancer risk or progression, then genetic
variants associated with metabolic effects of alcohol or
increased intake will be differentially represented in cases and
controls. We stratiﬁed the analysis by histological prostate
cancer grade, based on Gleason score, as low- and high-grade
prostate cancers have differing natural histories which could
be inﬂuenced by different risk factors.
Material and Methods
Study populations
We used phenotypic and genotypic data from 46,919 men
(23,868 cases) in the international Prostate cancer association
group to investigate cancer-associated alterations in the
genome (PRACTICAL) consortium. Data were provided by
25 studies within the consortium, based in USA, Australia
and European countries. This study population was limited
to those of European ethnicity. The studies used a number of
methods of recruitment, including screen and clinically
detected cases and participants selected due to a family histo-
ry of prostate cancer. The background characteristics of the
participants of each study are shown in Table 1. Gleason
scores were used to categorise cancers as low grade (Gleason
score 6) or high grade (Gleason score 7). Further details
are available from the consortium website (practical.ccge.-
medschl.cam.ac.uk). All studies adhered both to national ethi-
cal guidelines and to the principles of the Declaration of
Helsinki.
Genotyping data
The participants were genotyped using a custom Illumina
Inﬁnium genotyping array (iCOGS), which was speciﬁcally
designed for the Collaborative Oncological Gene-
environmental Study (COGS) and recorded 211,155 SNPs
(details available from: http://ec.europa.eu/research/health/
medical-research/cancer/fp7-projects/cogs_en.html).25,26 The
iCOGS array was designed to investigate SNPs in regions
thought to be associated with breast, ovarian and prostate
cancer; 68,638 of the SNPs on the array were chosen because
of their potential role in prostate cancer aetiology. The other
125,877 SNPs were selected on the basis of potential impor-
tance for other cancers and common SNPs known to be
associated with any other traits. Individuals with fewer than
95% of genotypes called, or high or low heterozygosity (p< 1
3 1025) were dropped from our analysis. In total 201,598
SNPs passed quality control. The genotypic data were used to
impute SNPs which were not directly genotyped, but were
in linkage disequilibrium (LD) with genotyped SNPs. We
used the HapMap 2 CEU reference panel and IMPUTE2
software.27
In this study, we searched the iCOGS array database for all
alcohol-metabolising genetic variants (within Alcohol Dehy-
drogenases (ADHs) or Aldehyde Dehydrogenases (ALDHs)
genes), and identiﬁed 68 common variants in 5 distinct geno-
mic regions: the ADH cluster on chromosome 4, comprising
ADH1A, ADH1B, ADH1C and ADH7; ALDH1A1 and ALDH
1B1 on chromosome 9; ALDH1A2 and ALDH1A3 on chromo-
some 15. Of these SNPs, 67 were directly genotyped, and
one was imputed. An overview of the genes’ role in alcohol
metabolism and behaviour is shown in Supplementary material
C
an
ce
r
E
pi
de
m
io
lo
gy
4 Alcohol metabolism and prostate cancer
Int. J. Cancer: 00, 00–00 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
Table S1. The characteristics of the SNPs included in this study
are shown in Supplementary material Table S2.
Statistical analysis
We converted the genotypic data for each SNP into a count of
the number of minor alleles at each locus. We used logistic
regression to estimate the associations of the SNPs with prostate
cancer risk (cases vs. controls), for all cases and stratiﬁed by
high- vs. low-grade disease. In a case-only analysis, we used Cox
proportional hazards regression to estimate associations of each
SNP with prostate cancer-speciﬁc mortality, stratiﬁed by grade
of prostate cancer. All regression analyses were adjusted for the
ﬁrst 8 principal components of population stratiﬁcation, since
these genomic regions show marked variation across different
populations and so do prostate cancer incidence and survival.
When checking the proportional hazards assumption, we found
little evidence of violation. These regressions were performed for
each study and then meta-analysed using both ﬁxed- and
random-effects models. Studies were excluded from the survival
meta-analysis if there were <5 deaths during the follow up peri-
od or <90% completion of follow up data. We investigated
between-study heterogeneity using the Stata metan command to
estimate the I2 statistic assuming a ﬁxed-effect model; we also
report random-effect models for completeness as such models
may be relevant where I2 values are high (e.g., >75%).28 Using
meta-regression, we investigated whether heterogeneity could be
explained by the following a priori deﬁned study-speciﬁc charac-
teristics: mean age at diagnosis, mean PSA at diagnosis, country
of study (USA vs. elsewhere), and the percentage of participants
with a family history of prostate cancer. Manhattan plots of the
associations in the ﬁve chromosomal regions were constructed
to identify SNPs exceeding the Nyholt corrected p values thresh-
old for association —a multiple testing correction which
accounts for LD between the SNPs.29
Sensitivity analyses were conducted by reclassifying low- and
high-grade disease as <8 and 8–10 Gleason grade, respectively.
The power of our study was also assessed using reverse
power calculations to demonstrate the effect size we would
Table 1. Background information on participants contributing to the PRACTICAL Consortium by study
Age at
diagnosis PSA level at diagnosis (ng/ml)
Family history Gleason score
Study Country Controls Cases Mean SD Median Lower quartile Upper quartile of disease 8–10
CAPS Sweden 664 1,153 66.10 7.75 13.0 7.0 30.0 17.35% 15.26%
CPCS1 Denmark 2,771 848 69.51 7.91 15.0 8.0 37.5 8.21% 26.65%
CPCS2 Denmark 1,009 265 64.88 6.82 9.0 6.0 14.5 14.72% 9.06%
EPIC Europe 1,079 722 64.87 5.62 8.6 6.0 15.9 – 2.22%
EPIC-Norfolk UK 917 484 72.08 7.56 19.8 19.8 19.8 2.48% 1.86%
ESTHER Germany 318 313 65.52 5.09 6.9 5.0 14.0 10.54% 8.63%
FHCRC USA 730 761 59.73 7.18 6.4 4.7 9.8 21.68% 10.38%
IPO-Porto Portugal 66 183 59.33 5.23 7.4 5.5 10.1 20.00% 15.85%
MAYO USA 488 767 65.24 6.42 7.8 4.9 14.7 29.07% 28.42%
MCCS Australia 1,170 1,698 58.45 8.46 5.4 0.0 11.4 23.45% 10.31%
MEC USA 829 819 69.53 7.62 – – – 13.03% 34.55%
MOFFITT USA 100 414 64.97 8.27 5.6 4.3 7.4 22.76% 11.11%
PCMUS Bulgaria 140 151 69.27 8.71 15.8 7.4 34.0 5.30% 29.80%
PPF-UNIS UK 188 245 68.86 7.57 8.6 6.3 14.0 25.22% 9.39%
Poland Poland 359 438 67.66 7.84 11.0 6.9 26.0 10.57% 11.42%
ProMPT UK 0 166 66.33 8.64 8.8 5.7 15.3 34.62% 16.87%
ProtecT UK 1,474 1,542 62.76 5.11 5.1 3.8 8.2 7.91% 5.64%
QLD Australia 87 186 61.32 6.91 5.2 2.2 7.5 36.18% 3.76%
SEARCH UK 1,244 1,371 63.08 4.76 8.8 5.6 15.0 16.24% 10.14%
STHM1 Sweden 2,224 2,006 66.17 6.99 – – – 20.18% 7.93%
TAMPERE Finland 2,413 2,754 68.18 7.96 8.6 5.6 16.3 – 13.76%
UKGPCS UK 4,182 4,549 63.76 7.97 9.8 5.6 24.7 23.42% 14.13%
ULM Germany 354 603 63.78 6.66 9.0 6.0 15.1 44.94% 12.11%
UTAH USA 245 440 62.57 8.85 – – – 51.36% 15.45%
WUGS USA 0 990 60.80 7.03 5.0 4.0 7.0 42.43% 7.88%
Abbreviations: SD, standard deviation; PSA, prostate-specific antigen.
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expect to detect given our sample size and a5 0.05 with
SNPs of a range of minor allele frequencies.30 The analysis
was carried out using Stata v.13.1. The statistical code used
to produce these results can be accessed here (https://github.
com/nmdavies/practical-alcohol/).
Results
The background characteristics of the participants are sum-
marised in Table 1, by study. Variation between studies
reﬂects their individual recruitment methods (e.g., some
studies selected for those men with a positive family history
of prostate cancer).
The Manhattan plots with results from both ﬁxed and
random effects meta-analyses testing associations between
SNPs in the ﬁve genomic regions and prostate cancer risk are
presented in Figure 1 (detailed results available in Supple-
mentary material Tables S4–S9, and sensitivity analyses with
alternative deﬁnitions of low- and high-grade presented in
Supplementary material Tables S16–S19). The ﬁgure and
Supplementary material tables show that no SNP exceeded
Figure 1. Manhattan plots of association of SNPs, in 5 regions involved in alcohol metabolism, with Prostate Cancer Diagnosis by Prostate
Cancer grade.
Figure 2. Manhattan plots of association of SNPs, in 5 regions involved in alcohol metabolism, with prostate cancer-specific survival by
prostate Cancer grade.
C
an
ce
r
E
pi
de
m
io
lo
gy
6 Alcohol metabolism and prostate cancer
Int. J. Cancer: 00, 00–00 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
the Nyholt corrected p values threshold for association with
prostate cancer risk.
In case-only analyses, four SNPs exceeded the Nyholt
corrected p values threshold for association with prostate
cancer-speciﬁc mortality in the ﬁxed-effect meta-analysis
(summary Manhattan plots presented in Figure 2, and indi-
vidual SNP results presented in Supplementary material
Tables S10–S15, with results of sensitivity analyses with
alternative deﬁnitions of low- and high-grade presented in
Supplementary material Tables S20–S23). Three SNPs with-
in ALDH1A2 were associated with prostate cancer mortali-
ty following diagnosis with any prostate cancer: rs1441817
(ﬁxed effects hazard ratio, HRﬁxed5 0.78; 95% conﬁdence
interval (95%CI):0.66,0.91, p values5 0.002, I25 19.4);
Figure 3. Meta-analysis of prostate cancer-specific survival following a diagnosis of any prostate cancer, in association with rs1441817 in
ALDH1A2. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 4. Meta-analysis of prostate cancer-specific survival following a diagnosis of low grade prostate cancer, in association with
rs10973794 in ALDH1B1. [Color figure can be viewed at wileyonlinelibrary.com]
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rs12910509, HRﬁxed5 0.76; 95%CI:0.64,0.91, p val-
ues5 0.003, I25 23.0); and rs8041922 (HRﬁxed5 0.76;
95%CI:0.64,0.91, p values5 0.002, I25 25.5). To identify
the top independent signal amongst these three, we con-
ducted jointly adjusted analyses. Levels of pairwise LD were
too high to attempt study-speciﬁc analyses (pairwise LD
rs1441817 and rs12910509 r25 0.89, rs1441817 and
rs8041922 r25 0.88, rs12910509 and rs8041922 r25 0.99).31
Pooled analyses were conducted to estimate the joint effects
of rs1441817 and rs12910509/rs8041922 (r25 0.99) on
prostate cancer survival, with a random effect correction
for standard errors. These showed an independent effect of
rs1441817, similar in size to that of univariate analyses, but
no independent effect of rs12910509/rs8041922 once
adjusting for rs1441817. Given the high LD between the
three SNPs, they should be taken as representing one
underlying genetic signal. Figure 3 presents the forest plot
of individual studies contributing to the meta-analysis of
prostate cancer-speciﬁc survival in association with the top
independent signal in ALDH1A2. A fourth SNP,
rs10973794 in ALDH1B1 (also close to IGFBPL1), was
associated with prostate cancer mortality in men with a diag-
nosis of low-grade prostate cancer (HRﬁxed5 1.43;
95%CI:1.14,1.79, p values5 0.002, I25 23.4, Fig. 4). This result
was robust to changing the low-grade deﬁnition to
<8 (HRﬁxed5 1.23; 95% CI:1.06,1.41, p values5 0.002, I
25 0,
Supplementary material Table S22).
In general, random effects meta-analyses yielded weaker
evidence of association than ﬁxed-effect models, as one
would expect due to variability across studies producing larg-
er conﬁdence intervals for the former. However, levels of het-
erogeneity as quantiﬁed by the I2 statistics were low, with
point estimates remarkably similar across the two types of
meta-analysis. Meta-regression analyses found limited evi-
dence that the study-level characteristics examined had a
strong inﬂuence on the pooled results (Table 2).
Discussion
Using data from the PRACTICAL Consortium, we pooled
data from 25 studies including a total of 23,868 prostate can-
cer cases and 23,091 controls, to investigate the association of
68 SNPs within genes thought to be involved with alcohol
metabolism with prostate cancer risk and prostate cancer-
speciﬁc mortality (amongst men diagnosed with prostate can-
cer), overall and by Gleason grade. After correcting for multi-
ple testing in the ﬁxed-effect meta-analysis, no SNPs exceed
the Nyholt threshold for association with a diagnosis of pros-
tate cancer, whereas three SNPs in ALDH1A2 (in strong LD
with each other, therefore representing one signal only)
exceed the Nyholt threshold for association with prostate
cancer-speciﬁc survival. One SNP in ALDH1B1 also exceeds
the Nyholt threshold for association with prostate cancer-
speciﬁc survival in low-grade prostate cancer.
Genetic variants in alcohol metabolising genes
There is evidence that genetic variations in ADH and ALDH
genes affecting ethanol metabolism32–35 are associated with
altered alcohol intake and risk of alcohol dependence.31,35–37
The most extensively studied SNP in the context of alcohol
intake is rs1229984 in ADH1B. It has been shown to be asso-
ciated with increased adverse effects from alcohol intake and
reduced consumption.35,36 On average minor allele carriers
drink 17.2% fewer units/week (95%CI:15.6%, 18.9%), are less
likely to be in the top third of alcohol drinking volume (odds
ratio, OR5 0.7; 95%CI:0.68,0.73) and are less likely to binge
drink (OR5 0.78; 95%CI:0.73,0.84).23 It has also been
reported to affect cancer risk at various sites.5 In our study,
the associations of this SNP with prostate cancer diagnosis
and survival were ORﬁxed5 1.00 (95%CI:0.96,1.03, p val-
ues5 0.87), and HRﬁxed5 1.11 (95%CI:0.95,1.30, p val-
ues5 0.17), respectively. Combining the effects of the
ADH1B SNP on alcohol intake with the upper conﬁdence
intervals from our results implies that a 17% reduction in
Table 2. Results of univariate meta-regressions to test if the association of the two SNPs (representing the two signals observed) is affected
by selected study characteristics
Confidence intervals
Single nucleotide polymorphism Study characteristic Ratio of odds-ratios Lower Upper p Values
rs1441817 PSA 1.48 0.75 2.93 0.19
(ALDH1A2) FHX 0.63 0.35 1.14 0.10
USA 0.69 0.30 1.57 0.30
Age 1.58 1.00 2.51 0.05
rs10973794 PSA 0.65 0.23 1.80 0.33
(ALDH1B1) FHX 0.65 0.25 1.68 0.27
USA 1.30 0.29 5.72 0.65
Age 1.30 0.62 2.72 0.40
PSA, mean PSA at diagnosis.
FHX, percentage family history.
USA, study location in USA vs. rest of world.
Age, mean age at diagnosis.
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alcohol consumption is unlikely to reduce prostate cancer
risk by >3% and prostate cancer mortality by >5%.
Alcohol is metabolised to acetaldehyde, a known carcino-
gen, and there is evidence to support the theory that genetic
variants in alcohol metabolising genes, which control the pro-
duction and breakdown of acetaldehyde, contribute to carci-
nogenesis.4,5,20,24 There is also evidence of a tissue-speciﬁc
interaction in the prostate between ethanol and retinoic acid,
through modulations of ALDH1A1, ALDH1A2 and
ALDH1A3 levels.38 To our knowledge, this is the ﬁrst com-
prehensive investigation of the association between ADH and
ALDH variants, as genetic proxies for alcohol, and prostate
cancer to date. Genetic predisposition to prostate cancer has
been examined by GWASs, which shows common genetic
variants can explain 33% heritability of prostate cancer but
no genome-wide signiﬁcant hits are in ADHs or ALDHs39,40
(however, this lack of evidence from GWASs could be a type
2 error). Similarly, we did not ﬁnd any evidence of genetic
association between ADH/ALDH variants and prostate can-
cer incidence in this study. Possible reasons for this include
type 2 error, especially if the underlying effects of alcohol on
prostate cancer incidence are small and limited to the very
heavy drinking behaviours and/or to the more aggressive
forms of disease, as possibly suggested by the recent
literature.7,12
We have shown that SNPs in ALDH1A2 are associated
with altered prostate cancer-speciﬁc mortality in a case-only
analysis. None of these SNPs appear to have regulatory fea-
tures (www.ensemble.org), so they are unlikely to be causal
variants themselves but rather they could be in LD with the
causal variants. Recently, ALDH isoforms have been sug-
gested as possible mechanistic mediators of metastasis in
prostate cancer in particular41 and other solid tumours in
general.42 One study found lack of compelling evidence link-
ing variation in ALDH1 (including ALDH1A1, ALDH1A2,
ALDH1A3 and ALDH1B1) with prostate cancer progres-
sion,41 but another had reported preliminary evidence for a
potential role of ALDH1A2 as a tumour suppressor gene in
prostate cancer cell lines43 and decreased expression of
ALDH1A2 has been associated with shorter recurrence free
survival in patients with prostate cancer.43 In our study, three
intronic SNPs in ALDH1A2 were associated with longer sur-
vival, none of which were directly or indirectly (through LD)
associated with alcohol-related phenotypes (http://www.ebi.ac.
uk/gwas/). One potential explanation for our results may be
that these SNPs, or others in LD with them, lead to increased
activity in ALDH1A2. We speculate that the observed pros-
tate cancer survival effect could be the result of a net increase
in the synthesis of retinoic acid (by ALDH1A2), which is
particularly beneﬁcial when the rate of conversion is affected
by slower ADH activity in the presence of alcohol consump-
tion (retinol and ethanol both being ADH substrates,44 and
ethanol modulating retinoic acid synthesis in the rat
prostate38).
Another intronic SNP in ALDH1B1 (also close to
IGFBPL1) was found to be associated with increased mortali-
ty following a diagnosis of low-grade prostate cancer.
ALDH1B1 is the second most abundant mitochondrial
ALDH, after ALDH2, with documented involvement in alco-
hol metabolism and dependence.45 However, this speciﬁc
SNP is not known to be in LD with any of the variants asso-
ciated with alcohol phenotypes to date, therefore we cannot
speculate on its speciﬁc role in relation to alcohol. Evidence
has been previously found linking levels of ALDH1B1 to sur-
vival following gastric cancer46 and non-small-cell lung can-
cer,47 but not prostate cancer,41 however the latter was a
study in vitro Conversely,ALDH1A1 expression in the pros-
tate has been reported to be a good candidate prognostic bio-
marker, based on all cause mortality and to a lesser extent
prostate cancer-speciﬁc mortality,48 and ALDH1A3 expres-
sion is thought to be involved with initiation and progression
of several cancers,49 however we did not observe an associa-
tion with common germ-line mutations in either of these
genes, or did we observe associations with variation in ADH
genes. This could be due to different functional effects of var-
iants on metabolic levels (e.g., alcohol and acetaldehyde peak
levels and cumulative concentrations), affecting prostate can-
cer proliferation or survival differently both in terms of effect
sizes and pathways.
Differences by tumour grade
In this study, we have found that genetic variants in genes
involved in alcohol metabolism were associated with disease-
speciﬁc mortality in men with prostate cancer, most of
whom had been diagnosed with low-grade disease. We found
a signal speciﬁc to low-grade prostate cancer survival, but
none for high-grade disease. Possible reasons why stronger
associations were not seen with high-grade cancers include:
limited power, as there were smaller numbers of high- com-
pared with low-grade cases (this was investigated using a
reverse power calculation, to assess the power of this study to
detect small associations (Supplementary material Table S3));
patients behaviour may change following a diagnosis, e.g.
patients with high-grade prostate cancer may be too ill to
drink and the effect of the SNPs cannot be seen in the
absence of drinking; or the ﬁndings could reﬂect a true clini-
cal difference in the way alcohol affects survival for the dif-
ferent grades of prostate cancer.
Strengths and limitations
The strengths of this study include the large sample size and
availability of data on both risk and mortality stratiﬁed by
grade, which is an important predictor of prognosis. Impor-
tantly, we used a Mendelian randomisation approach, which
minimises the potential for bias due to confounding, infor-
mation bias (recall bias and sick-quitter effect) and reverse
causation, major limitations of previous studies in this
area.7,8,13 We were also able to control for confounding by
population stratiﬁcation by adjusting for basic population
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characteristics. A potential limitation of our study is its pow-
er to detect small effects of alcohol on high-grade disease,
with fewer of these cases having been diagnosed and fol-
lowed-up.
Data for this study were contributed to the PRACTICAL
Consortium from many studies with varying recruitment and
inclusion/exclusion criteria, as different screening practices
could complicate the interpretation of our results.50 For
example, CAPS participants were all diagnosed clinically,
whereas ProtecT participants were all screen detected. While
the consortium provides a large sample size for investigation,
there is inevitably some heterogeneity in the contributing
studies. The effect of this was investigated using random
effects meta-analysis and meta-regression. No one study-level
characteristic had a strong inﬂuence on the results, and we
were unable to clearly determine the reason for the modest
levels of heterogeneity observed, and the consequent variation
between the ﬁxed-effect and random-effect analyses. Potential
explanations include: systematic differences in smaller vs.
larger studies, and the former being assigned larger weights
in random-effect models; true variation in the effects of alco-
hol in the different study populations; effects of study designs
that we were not able to investigate, e.g. the different ways
cases were ascertained/recruited.
Another possible limitation to consider is the potential
inﬂuence of pleiotropy. There may be other direct pathways
through which the SNPs inﬂuence prostate cancer mortality
independently of alcohol metabolism and intake. In particu-
lar, SNPs in ALDH1A2 could have a role in retinoic acid
synthesis, which could affect cancer survival per se and in
conjunction with alcohol,38 and we note that the ALDH1B1
SNP is in close proximity to IGFBPL1, which may encode a
putative tumour suppressor protein.51 However, there were
no other associations of these SNPs, or others in LD with
them, reported by the catalogue of published genome-wide
association studies (http://www.ebi.ac.uk/gwas/); therefore the
risk of pleiotropy for the genetic variants under study here is
likely to be small. Finally, the direction of effect of the SNPs
on alcohol intake, apart from rs1229984, is unknown so it is
not possible to estimate the effect size of the four SNPs we
found to be associated with survival.
Future directions
There are a number of ways in which this work could be tak-
en forward. These include further analysis in larger consortia
with longer follow up data availability, or repeating within
individual subsets with certain study design characteristics to
increase similarity of studies included in analysis (direct rep-
lication). Analysis of further genetic variants with known
effects on alcohol metabolism or behaviour would also allow
further development of this work (indirect replication), as
would establishing the magnitude and direction of effect of
genetic variants in alcohol metabolising genes on alcohol
intake. It would also be interesting to investigate patient
behaviour following diagnosis to establish if the varied effect
seen between high- and low-grade disease could be due to
differences in behaviour.
Conclusion
If conﬁrmed in independent studies or through direct or
indirect replication, these ﬁndings suggest a role for alcohol
in the progression of prostate cancer, whilst also conﬁrming
that alcohol is unlikely to have a large impact on prostate
cancer carcinogenesis. This has potential public health impli-
cations and alcohol intake could be targeted to improve sur-
vival from prostate cancer as part of holistic care.
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